Free Trial

Harmony Biosciences (HRMY) Competitors

$29.33
-0.09 (-0.31%)
(As of 04:00 PM ET)

HRMY vs. KURA, EWTX, GPCR, NAMS, SNDX, SDGR, TARO, ARDX, RCUS, and LGND

Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Kura Oncology (KURA), Edgewise Therapeutics (EWTX), Structure Therapeutics (GPCR), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), Schrödinger (SDGR), Taro Pharmaceutical Industries (TARO), Ardelyx (ARDX), Arcus Biosciences (RCUS), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry.

Harmony Biosciences vs.

Kura Oncology (NASDAQ:KURA) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.

Kura Oncology has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Kura Oncology currently has a consensus price target of $27.94, suggesting a potential upside of 35.16%. Harmony Biosciences has a consensus price target of $40.63, suggesting a potential upside of 41.35%. Given Kura Oncology's higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than Kura Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Harmony Biosciences
2 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.50

Harmony Biosciences has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura OncologyN/AN/A-$152.63M-$2.17-9.65
Harmony Biosciences$582.02M2.85$128.85M$2.3112.63

86.2% of Harmony Biosciences shares are owned by institutional investors. 5.5% of Kura Oncology shares are owned by company insiders. Comparatively, 30.8% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kura Oncology received 362 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 69.01% of users gave Kura Oncology an outperform vote while only 60.29% of users gave Harmony Biosciences an outperform vote.

CompanyUnderperformOutperform
Kura OncologyOutperform Votes
403
69.01%
Underperform Votes
181
30.99%
Harmony BiosciencesOutperform Votes
41
60.29%
Underperform Votes
27
39.71%

Harmony Biosciences has a net margin of 22.30% compared to Harmony Biosciences' net margin of 0.00%. Kura Oncology's return on equity of 28.26% beat Harmony Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kura OncologyN/A -37.52% -34.11%
Harmony Biosciences 22.30%28.26%17.23%

In the previous week, Kura Oncology had 1 more articles in the media than Harmony Biosciences. MarketBeat recorded 5 mentions for Kura Oncology and 4 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.06 beat Kura Oncology's score of 0.70 indicating that Kura Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kura Oncology
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Harmony Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Harmony Biosciences beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRMY vs. The Competition

MetricHarmony BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.66B$6.64B$4.96B$8.05B
Dividend YieldN/A2.77%2.80%3.97%
P/E Ratio12.6312.15139.1615.77
Price / Sales2.85247.342,450.0972.66
Price / Cash11.4833.0734.6931.30
Price / Book3.215.815.474.57
Net Income$128.85M$137.94M$104.51M$213.29M
7 Day Performance-3.35%-1.50%-0.92%-1.13%
1 Month Performance-0.24%1.08%2.20%2.17%
1 Year Performance-17.94%-3.34%4.92%6.99%

Harmony Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KURA
Kura Oncology
3.4459 of 5 stars
$22.11
-0.6%
$27.94
+26.4%
+61.0%$1.68BN/A-10.19142Positive News
EWTX
Edgewise Therapeutics
1.6777 of 5 stars
$17.89
-4.7%
$31.20
+74.4%
+71.1%$1.67BN/A-11.5492Positive News
Gap Down
GPCR
Structure Therapeutics
1.9051 of 5 stars
$35.81
+0.1%
$85.71
+139.4%
+15.9%$1.67BN/A-46.5193Gap Up
NAMS
NewAmsterdam Pharma
3.7085 of 5 stars
$19.48
-1.8%
$33.25
+70.7%
+43.0%$1.75B$14.09M0.0029Short Interest ↓
SNDX
Syndax Pharmaceuticals
3.7154 of 5 stars
$20.66
+2.0%
$34.42
+66.6%
+0.4%$1.76B$139.71M-6.42184Positive News
SDGR
Schrödinger
2.6972 of 5 stars
$22.04
-2.5%
$42.80
+94.2%
-38.6%$1.60B$216.67M-11.72867Positive News
Gap Down
TARO
Taro Pharmaceutical Industries
0.8288 of 5 stars
$42.58
+0.4%
$43.00
+1.0%
+45.2%$1.60B$572.95M34.901,554Analyst Forecast
Short Interest ↑
ARDX
Ardelyx
4.6354 of 5 stars
$7.72
-2.6%
$12.81
+66.0%
+111.0%$1.80B$124.46M-27.57267Short Interest ↓
Gap Down
RCUS
Arcus Biosciences
1.4363 of 5 stars
$17.23
+2.7%
$41.25
+139.4%
-28.9%$1.57B$117M-5.54577Gap Down
LGND
Ligand Pharmaceuticals
4.7199 of 5 stars
$87.00
+0.4%
$116.33
+33.7%
+19.2%$1.57B$131.31M16.8358Positive News

Related Companies and Tools

This page (NASDAQ:HRMY) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners